Related Experiment Video
Updated: May 11, 2026

Protocols for Robust Herbicide Resistance Testing in Different Weed Species
Published on: July 2, 2015
Metabolic resistance to bensulfuron-methyl endowed by the CdCYP71FL1 gene in Cyperus difformis from China
Yonglin Ma1, Mengge Huang1, Jianying Qin2
1Key Laboratory of Green Prevention and Control on Fruits and Vegetables in South China Ministry of Agriculture and Rural Affairs, Guangxi Key Laboratory of Biology for Crop Diseases and Insect Pests, Plant Protection Research Institute, Guangxi Academy of Agricultural Science, Nanning 530007, China.
Abstract:
Cyperus difformis is a problematic weed in direct-seeded rice fields in China. Due to long-term selection pressure from herbicides, C. difformis has evolved resistance to bensulfuron-methyl (BSM). Our previous study revealed the existence of both target-site gene mutations and metabolic resistance mechanisms in the HN-8 population. However, the specific mechanisms of metabolic resistance were not fully understood and therefore were investigated further. The resistant HN-8 population, compared to the susceptible population, exhibited over-expression of six cytochrome P450 monooxygenases (CYPs), five ATP-binding cassette transporters (ABCs), one UDP-glucuronosyltransferases (UGT), and one Glutathione S-transferase (GST). Notably, three CYPs were identified as CdCYP71FL1, CdCYP74B57, and CdCYP94C180, with CdCYP71FL1 being induced by BSM in the HN-8 population. Heterologous expression of CdCYP71FL1 in Arabidopsis thaliana conferred resistance to BSM, bispyribac‑sodium, and bentazone, while its expression in yeast facilitated the degradation of BSM. These results indicate that CdCYP71FL1 plays an important role in the metabolic resistance observed in the HN-8 population. Given the complexity of metabolic resistance compared to target-site resistance, it is crucial to prioritize tailored management strategies for herbicide-resistant weeds driven by metabolic mechanisms.
Related Concept Videos
Treatment Resistant Cancers
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

